`We Make It Happen ~
`
`Planet Depos
`
`Transcript of Video - What You
`Need to Know About Mavenclad
`
`Planet Depos
`
`
`Phone: 888-433-3767 EXHIBIT_XJOS
`
`
`
`Wit:__Fax: 888-503-3767 MN iflerSoeera
`, /,7~72: DATE:
`
`
`
`Email: transcripts@planetdepos.com pate:/d~/A-93
`
`
`
`
`med HAMILTON, ROR
`www.planetdepos.com
`
`
`
`
`
`WORLDWIDE COURT REPORTING & LITIGATION TECHNOLOGY
`
`MERCK2008
`HOPEWELL v MERCK
`IPR2023-0048 1
`
`MERCK 2008
`HOPEWELL v MERCK
`IPR2023-00481
`
`
`
`=
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`d7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`RECORDED VIDEO - WHAT YOU NEED TO KNOW ABOUT
`
`MAVENCLAD
`
`https://www.nationalmssociety.org/Treating-MS/Medications/Mavenclad
`
`Job Now:
`
`514115
`
`Pages: 1- 14
`
`Transcribed by: Lauren Bishop
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`DR. AARON MILLER, MD: It's always exciting
`
`to have a new medication for the treatment of
`
`multiple sclerosis.
`
`In this case, we're going to be
`
`talking about a new medicine called Mavenclad. The
`
`scientific name for Mavenclad is Cladribine. And
`
`Cladribine has been used has been approved to be used
`
`in patients with relapsing, remitting multiple
`
`sclerosis and secondary progressive MS with activity.
`
`isolated syndrome. Other forms of MS are progressive
`
`
`
`So nowadays, we classify multiple sclerosis into
`
`several different types. One is relapsing remitting
`
`MS. These are people who have clear cut relapses and
`
`then a relapse resolves often completely. Sometimes
`
`leaving some degree of neurological deficit behind
`
`until another relapse comes.
`
`At the very first episode of MS, a first
`
`attack of something that looks like MS, we may refer
`
`to that as a clinically isolated syndrome, meaning a
`
`person doesn't meet the criteria for definite MS yet.
`
`In some cases we may treat patients with CIS with
`
`certain medicines, but specifically Mavenclad has not
`
`been approved for the treatment of clinically
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`disease, and we have two types of progressive
`
`disease. Secondary progressive disease and primary
`
`in a person who once upon a time had at least one
`
`relapse and then ultimately the disease course
`
`changes so that the person is little by little
`
`getting worse.
`
`progressive MS. Secondary progressive MS is diagnosed
`
`the FDA did not apply a time
`
`Primary progressive MS refers to a patient
`
`who from the very beginning had a progressive course.
`
`Relapses are sometimes superimposed later on but the
`
`initial course was progressive.
`
`Nowadays, however, we apply modifiers to
`
`these Progressive courses depending on whether or not
`
`an individual has what we refer to as activity.
`
`Activity could either be clinical activity that is a
`
`relapse or it could be new lesions on MRI. So the FDA
`
`in approving Mavenclad for the very first time use
`
`the term secondary progressive MS with activity so
`
`that means a person who has been getting
`
`progressively worse, but in the recent past has had
`
`either new relapses or new lesions appearing on the
`
`MRI scan. Interestingly,
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`frame for what they meant by activity. Usually
`
`clinicians will be thinking about activity in the
`
`relatively recent past. Let's say the past year or
`
`two, but the FDA specifically did not mention that in
`
`the prescribing information for Mavenclad.
`
`Mavenclad is a drug which interferes with
`
`the synthesis and repair of DNA in certain cells and
`
`by interfering with these processes, it kills certain
`
`cells.
`
`In particular, it's use in MS has come about
`
`because the substrate for Mavenclad is particularly
`
`concentrated in lymphocytes. And so the drug has a
`
`particularly strong effect in destroying lymphocytes.
`
`Lymphocytes are a form of immune cells that are
`
`involved in the MS process and lymphocytes come in
`
`two major varieties, T cells and B cells. And both of
`
`these are affected by Mavenclad.
`
`The treatment regimen for Mavenclad is
`
`rather unique. So Mavenclad is a -- a tablet. It
`
`comes as a 10-milligram tablet and the dose of
`
`Mavenclad is dependent on an individual's weight.
`
`This is the only MS medicine that we have that is not
`
`given in a fixed dose but rather the dose is
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`determined by how much the individual weighs.
`
`Mavenclad is given in -- in courses so that the first
`
`So in order for a drug to be approved by
`
`course starts at the beginning and you get you get
`
`two cycles approximately a month apart. So at the
`
`very beginning, you take a number of tablets over 4
`
`to 5 days, exactly how many tablets again depending
`
`on the weight and then you wait between three and
`
`four weeks to get the -- the second part of that
`
`course,
`
`the second cycle in that treatment phase. And
`
`after that second course, so now you're roughly one
`
`month into treatment,
`
`then you have the rest of the
`
`year off and you come back at the beginning of the
`
`second year and you get another cycle. Again, another
`
`course rather of two cycles about a month apart with
`
`the same dose that you got at the beginning. After
`
`that you don't get any more medicine. Mavenclad by
`
`the FDA's recommendation is considered a second-line
`
`therapy. Meaning that the recommendation is that a
`
`person either have had breakthrough disease on a
`
`previous therapy or has not tolerated previous
`
`therapy before Mavenclad is used.
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`the FDA, it has to go through phase 3 testing,
`
`the
`
`last stage of testing which is aimed at determining
`
`that a drug is effective as well as continuing to
`
`demonstrate a satisfactory safety profile that would
`
`allow the FDA to approve the drug.
`
`So the major phase three trial for -- for
`
`Mavenclad was known as the CLARITY trial and it
`
`involved over 1,300 patients. There were three arms
`
`in that trial. So close to 500 patients in each of
`
`the three arms. The primary endpoint of the trial was
`
`looking to see whether there would be a reduction in
`
`the annualized relapse rate. The number of relapses
`
`that an average individual had per year.
`
`So there was a roughly 58 percent
`
`reduction in the annualized relapse rate for -- for
`
`Mavenclad compared to Placebo. The investigations
`
`also looked at what we refer to as confirmed
`
`disability progression. That is a person who shows a
`
`worsening of their neurological examination to a
`
`certain degree specified by the protocol and then
`
`maintains that degree of worsening at least three
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`months later. That's referred to as 3-month confirmed
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`disease progression. And this was reduced by about 33
`
`percent in the patients taking Mavenclad. Also the
`
`use of Mavenclad was associated with an extremely
`
`robust reduction in MRI activity, both contrast
`
`enhancing lesions, which reflect active lesions or
`
`other types of lesions, which developed at some point
`
`lesser extent, more severe infections. Other side
`
`in the period between the prior MRI and the -- and
`
`the new MRI.
`
`So this drug is quite -- is quite
`
`effective and certainly compares favorably with the
`
`other oral drugs in terms of efficacy. Whenever we
`
`prescribe a drug for MS, we have to balance the
`
`potential benefits of the drug.
`
`In this case the
`
`reduction in relapse rate,
`
`the far fewer MRI lesions,
`
`the lower rate of disability progression against what
`
`are the tolerability issues of the drug and the
`
`potential -- potentially serious adverse events or
`
`side effects. Mavenclad appears to be very well
`
`tolerated. There is a slightly increased rate of
`
`headache with the drug and there are some slight
`
`increases in the risks of minor infections and to a
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`effects that we are concerned about, we need to watch
`
`out for liver injury. We get baseline liver function
`
`tests and monitor liver function in patients who are
`
`on Mavenclad. And one of the infections that we’re
`
`concerned about is the possibility of shingles which
`
`is caused by the varicella virus, which is the virus
`
`that also causes chickenpox. So the incidence of
`
`shingles is somewhat elevated in patients taking
`
`Mavenclad.
`
`Mavenclad is specifically relates to blood
`
`transplanted tissue of one type starts to attack the
`
`So one of the things we do before putting
`
`a person on this medication is check for their immune
`
`status to varicella. If they're not immune to
`
`varicella, we recommend the immunization with
`
`varicella vaccine and then that because it's a live
`
`virus vaccine should be given at least four to six
`
`weeks before one initiates treatment with Mavenclad.
`
`A rare thing that we need to consider is an entity
`
`called graft-versus-host disease. Graft-versus-—host
`
`disease is a an unusual situation in which
`
`recipient’s own tissue. The concern with regard to
`
`PLANETDEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`9
`
`transfusions. So if a person on Mavenclad needs to
`
`get a blood transfusion, graft versus host disease
`
`can prevent -- be prevented fairly simply and readily
`
`by irradiating the blood that's going to be
`
`transfused. But that is an important thing to
`
`remember all be it a relatively unusual situation.
`
`One of the major concerns that the FDA had
`
`about the safety of Mavenclad regard -- regards a
`
`potentially increased risk of cancer. So that's an
`
`increased risk, but it's a very low increased risk.
`
`It's also important to note that the cancers that
`
`occurred with Mavenclad were all different types of
`
`cancers. We -- the warning about cancer is in a boxed
`
`warning in the prescribing information, but I think
`
`it's important that patients understand that this
`
`does appear to be a very low risk.
`
`Another concern about Mavenclad is that it
`
`would have potential risks to a fetus if a woman were
`
`taking Mavenclad during pregnancy, so we strongly
`
`advise women not to get pregnant while they're taking
`
`Mavenclad. They should use effective contraceptive
`
`means and especially during their active cycles of
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`193
`
`20
`
`2 2
`
`2
`
`PLANETDEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`Mavenclad,
`
`they should use not only a hormonal
`
`contraceptive but also barrier methods. When the man
`
`is taking Mavenclad he should avoid impregnating a
`
`woman until six months after the dose and women
`
`should not attempt to get pregnant until six months
`
`after a course of Mavenclad.
`
`So the testing that we do before a patient
`
`goes on Mavenclad relate to some of these adverse
`
`events that we've been talking about. Mavenclad would
`
`have the risk of activating latent infections. So one
`
`of the infections that could be reactivated is
`
`tuberculosis. So we screen patients for tuberculosis.
`
`Another is hepatitis. So we recommend screening for
`
`Hepatitis B and Hepatitis C. Mavenclad should not be
`
`used in patients who are HIV positive. So we should
`
`screen for HIV prior to the use of Mavenclad. We also
`
`do routine blood counts and liver function testing.
`
`Again, we want to make sure that the lymphocyte count
`
`is at least a thousand prior to the first dose and at
`
`least 800 prior to the second dose of Mavenclad. And
`
`that I think pretty much encompasses the baseline
`
`testing that we want
`
`to do in a patient going on
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`Mavenclad. Of course for a woman we want
`
`to make sure
`
`that she's not pregnant.
`
`One of our concerns with a number of drugs
`
`that we use in MS is the risk of a brain infection
`
`called PML which stands for Progressive Multifocal
`
`Leukoencephalopathy. That's a mouthful so we will
`
`stick with PML. PML is caused by a virus that many of
`
`the drug to which you are switching, but also the
`
`us live with comfortably. It doesn't do any harm to
`
`people who are whose immune systems are not
`
`compromised. PML has not been reported with
`
`cladribine, with oral cladribine, but it is at least
`
`a theoretical risk because of the effect on the
`
`immune system that Mavenclad has. So patients before
`
`going on Mavenclad should have an MRI test not only
`
`to assess the status of their MS, but to look for any
`
`evidence that might exist for PML.
`
`Many people with MS start on a medication
`
`and then need to change medication at some point for
`
`one reason or another. Sometimes we need to do some
`
`advance planning or at least thinking about the
`
`timing in making a switch. And it depends not only on
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`Now in the case of Mavenclad that the main
`
`circumstance here would be that we need to have the
`
`lymphocyte count be up to 1,000. And some of the
`
`drugs that we -- that the person might have been on
`
`before Mavenclad may have suppressed the lymphocyte
`
`count. And so we may need to wait to get that
`
`lymphocyte count back into the safe range for
`
`drug that the patient has been on in the first place.
`
`relatively small copay. Even with that EMD Serono,
`
`Mavenclad. Mavenclad is generally not recommended as
`
`an initial therapy because of the safety concerns
`
`that it have been raised. It is on the market and
`
`available -- available for prescriptions.
`
`Unfortunately,
`
`like all of the other MS medications,
`
`it has an enormously high price tag.
`
`As providers, we only have access to
`
`average wholesale prices and what was listed for
`
`Mavenclad as I believe $99,000 so as with most other
`
`medications, we certainly don't expect that people
`
`with MS are going to be paying these kinds of prices
`
`for the drugs. Hopefully their insurer is going to
`
`cover the drug and the patient hopefully would have a
`
`PLANETDEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`the manufacturer of Mavenclad has a patient
`
`assistance program is available -- available. They
`
`offer co-pay assistance to many patients who are
`
`commercially insured.
`
`Decisions about what disease-modifying
`
`therapy to use are getting increasingly complex.
`
`That's actually good news because the reason they're
`
`complex is because we have so many good therapies and
`
`(The recording was concluded.)
`
`any therapy -- any choice of therapy entails and
`
`assessment of benefit versus risk. The benefits, of
`
`course in reducing MS activity and the risks variable
`
`depending on the particular medication.
`
`I think the best thing that a patient
`
`should do in is have a frank discussion with the
`
`healthcare provider. They should have an open
`
`discussion about what we know about the benefits of
`
`the drug and go over not only the serious risks, but
`
`any tolerability issues.
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`CERTIFICATE OF TRANSCRIBER
`
`I, Lauren Bishop, do hereby certify that
`
`that said transcript is a true and accurate
`
`transcription of the audio to the best of my
`
`knowledge, skills, and ability; and that I am neither
`
`counsel for, related to, nor employed by any of the
`
`parties to this case and have no interest, financial
`
`or otherwise,
`
`in its outcome.
`
`the transcript was prepared from the audio recording;
`
`November 14, 2023
`
`jue Luks
`
`LAUREN BISHOP
`
`Planet Depos,
`
`
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`allow
`6:5
`also
`
`6:17, 7:2, 8:7,
`9:11, 10:2,
`10:16, 11:22
`always
`2:1
`annualized
`
`6:12, 6:15
`another
`
`2:14, 5:13,
`9:17, 10:13,
`11:19
`
`any
`5:16, 11:8,
`11:15, 13:9,
`13:18, 14:7
`apart
`5:4, 5:14
`appear
`9:16
`
`appearing
`3:21
`
`6:8, 6:10
`assess
`11:15
`assessment
`13:10
`assistance
`
`13:2, 13:3
`associated
`7:3
`attack
`
`2:16, 8:20
`
`attempt
`10:5
`audio
`
`14:3, 14:5
`available
`
`12:12, 13:2
`average
`6:13, 12:16
`avoid
`10:3
`
`B
`
`back
`
`5:12, 12:8
`balance
`7:12
`barrier
`10:2
`baseline
`
`8:2, 10:21
`because
`
`4:10, 8:14,
`11:12, 12:10,
`13:7, 13:8
`been
`
`2:6, 2:21,
`3:19, 10:9,
`11:10, 12:1,
`12:5, 12:11
`before
`
`5:21, 8:10,
`8:16, 10:7,
`11:13, 12:6
`beginning
`3:9, 5:3, 5:5,
`5:12, 5:15
`behind
`2:13
`believe
`12:17
`benefit
`13:10
`benefits
`
`7:13, 13:10,
`13:16
`best
`
`13:13, 14:5
`between
`La WaT
`
`9:13, 9:17,
`10:9, 11:20,
`13:5, 13:16
`access
`12:15
`accurate
`14:4
`activating
`10:10
`active
`
`7:5, 9:22
`activity
`2:8, 3:14,
`3:15, 3:18, 4:1,
`4:2, 7:4, 13:11
`actually
`13:7
`advance
`11:20
`adverse
`
`7:17, 10:8
`advise
`9:20
`affected
`4:16
`after
`
`5:10, 5:15,
`10:4,
`:6
`again
`5:6, 5:
`10:18
`
`against
`7:15
`aimed
`6:2
`all
`
`9:6, 9:12,
`12:13
`
`8:11
`
`appears
`7:18
`apply
`3:12, 3:22
`approve
`6:5
`approved
`2:6, 2:21, 5:22
`approving
`3:17
`approximately
`5:4
`arms
`
`bishop
`1:22, 14:2,
`14:13
`blood
`
`8:22, 9:2, 9:4,
`
`breakthrough
`5:19
`
`Cc
`
`called
`
`2:4, 8:18, 11:5
`cancer
`
`9:9, 9:13
`cancers
`
`9:11, 9:13
`case
`
`2:3, 7:13,
`12:2, 14:8
`cases
`2:19
`caused
`
`8:6, 11:7
`causes
`8:7
`cells
`
`4:7, 4:9, 4:13,
`4:15
`certain
`
`2:20, 4:7, 4:8,
`6:20
`certainly
`7:10, 12:18
`certificate
`14:1
`certify
`14:2
`change
`11:18
`changes
`3:6
`check
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`4:19, 4:22,
`5:15, 10:4,
`10:19, 10:20
`dr
`2:1
`drug
`4:6, 4:11,
`5:22, 6:3,
`7:9, 7:12,
`7:16, 7:20,
`11:22, 12:1,
`12:21, 13:17
`drugs
`7:11, 11:3,
`12:5, 12:20
`during
`9:19, 9:22
`E
`
`13:9
`
`dose
`
`each
`6:9
`effect
`
`4:12, 11:12
`effective
`
`6:3, 7:10, 9:21
`effects
`
`7:18, 8:1
`efficacy
`7:11
`either
`
`3:15, 3:21,
`5:19
`elevated
`8:8
`emd.
`12:22
`
`employed
`14:7
`
`encompasses
`10:21
`endpoint
`6:10
`
`enhancing
`Thc,
`
`enormously
`12:14
`entails
`
`chickenpox
`8:7
`choice
`13:9
`circumstance
`12:3
`cis
`2:19
`cladribine
`
`2:5, 2:6, 11:11
`clarity
`6:7
`
`classify
`2:9
`clear
`2:11
`clinical
`3:15
`clinically
`2:17, 2:21
`clinicians
`4:2
`close
`6:9
`
`co-pay
`13:3
`come
`
`4:9, 4:14, 5:12
`comes
`
`2:14, 4:19
`comfortably
`11:8
`
`commercially
`13:4
`compared
`6:16
`
`compares
`7:10
`completely
`2:12
`complex
`13:6, 13:8
`compromised
`11:10
`concentrated
`4:11
`concern
`
`8:21, 9:17
`
`concerned
`
`8:1, 8:5
`concerns
`
`9:7, 11:3,
`12:10
`concluded
`13:19
`confirmed
`
`6:17, 6:22
`consider
`8:17
`considered
`5:17
`continuing
`6:3
`
`contraceptive
`9:21, 10:2
`contrast
`7:4
`
`copay
`12:22
`could
`
`3:15, 3:16,
`10:11
`counsel
`14:7
`count
`
`10:18, 12:4,
`12:7, 12:8
`counts
`10:17
`course
`
`3:5, 3:9, 3:11,
`5:3, 5:9, 5:10,
`5:14, 10:6,
`11:1, 13:11
`courses
`
`SIPS ae ET
`cover
`12:21
`criteria
`2:18
`cut
`2:11
`cycle
`5:9, 5:13
`cycles
`5:4, 5:14, 9:22
`
`days
`5:6
`decisions
`13:5
`deficit
`2:13
`definite
`2:18
`degree
`2:13, 6:20,
`6:21
`demonstrate
`6:4
`
`dependent
`4:20
`
`depending
`3:13, 5:6,
`13:12
`depends
`11:21
`
`depos
`14:14
`
`destroying
`4:12
`determined
`5:1
`determining
`6:2
`
`developed
`7:36
`diagnosed
`3:3
`different
`
`2:10, 9:12
`disability
`6:18, 7:15
`discussion
`
`13:14, 13:16
`disease
`
`3:1, 3:2, 3:5,
`5:19, 7:1, 8:18,
`8:19, 9:2
`disease-modifying
`13:5
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`entity
`8:17
`
`episode
`2:15
`
`especially
`9:22
`even
`
`12:22
`events
`
`7:17, 10:9
`evidence
`11:16
`
`exactly
`5:6
`examination
`6:19
`exciting
`2:1
`exist
`11:16
`
`expect
`12:18
`extent
`7:22
`extremely
`7:3
`
`F
`
`fairly
`9:3
`far
`7:14
`favorably
`7:10
`fda
`
`3:16, 3:22,
`4:4, 6:1, 6:5,
`9:7
`fda's
`5:17
`fetus
`9:18
`fewer
`7:14
`financial
`14:8
`first
`
`2:15, 3:17,
`
`5:2, 10:19, 12:1
`fixed
`4:22
`form
`4:13
`forms
`2:22
`four
`
`5:8, 8:15
`frame
`4:1
`frank
`13:14
`function
`8:2, 8:3, 10:17
`G
`
`H
`
`harm
`11:8
`headache
`7:20
`healthcare
`13:15
`hepatitis
`10:13, 10:14
`here
`12:3
`
`6:7
`
`generally
`12:9
`getting
`3:7, 3:19, 13:6
`given
`4:22, 5:2, 8:15
`go
`6:1, 13:17
`goes
`10:8
`going
`2:3, 9:4,
`10:22, 11:14,
`12:19, 12:20
`good
`13:7, 13:8
`graft
`9:2
`graft-versus-host
`8:18
`
`initial
`
`3:11, 12:10
`initiates
`8:16
`injury
`8:2
`insured
`13:4
`insurer
`12:20
`interest
`14:8
`interestingly
`3:22
`interferes
`4:6
`interfering
`4:8
`investigations
`6:16
`involved
`
`4:14, 6:8
`irradiating
`9:4
`isolated
`
`2:17, 2:22
`issues
`
`7:16, 13:18
`J
`
`job
`1:20
`
`kills
`4:8
`kinds
`12:19
`know
`
`1:7, 13:16
`knowledge
`14:6
`known
`
`hereby
`14:2
`high
`12:14
`hiv
`
`10:15, 10:16
`hopefully
`12:20, 12:21
`hormonal
`10:1
`host
`9:2
`however
`3:12
`
`https
`1:10
`
`immune
`
`4:13, 8:11,
`8:12, 11:9,
`11:13
`immunization
`8:13
`important
`9:5, 9:11, 9:15
`impregnating
`10363
`incidence
`8:7
`increased
`
`7:19, 9:9, 9:10
`increases
`7:21
`increasingly
`13:6
`individual
`
`3:14, 5:1, 6:13
`individual's
`4:20
`infection
`11:4
`infections
`
`7:21, 7:22,
`8:4, 10:10,
`10:11
`information
`
`4:5, 9:14
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`once
`
`2:4, 4:21, 5:16
`medicines
`2:20
`meet
`2:18
`mention
`4:4
`methods
`10:2
`might
`11:16, 12:5
`miller
`2:1
`milligram
`4:19
`minor
`7:21
`modifiers
`3:12
`monitor
`8:3
`month
`
`multifocal
`11:5
`multiple
`2:3, 2:7, 2:9
`N
`
`name
`2:5
`nationalmssociety
`1:10
`need
`
`1:7, 8:1, 8:17,
`11:18, 11:19,
`12:3, 12:7
`needs
`9:1
`neither
`14:6
`neurological
`2:13, 6:19
`new
`
`2:2, 2:4, 3:16,
`3:21, 7:8
`news
`13:7
`note
`9:11
`november
`14:15
`nowadays
`2:9, 3:12
`number
`
`5:5, 6:12, 11:3
`O°
`
`occurred
`9:12
`offer
`13:3
`often
`2:12
`
`medication
`
`2:2, 8:11,
`11:17, 11:18,
`13:12
`medications
`
`1:10, 12:13,
`12:18
`medicine
`
`5:4, 5:11, 5:14
`months
`
`6:22, 10:4,
`10:5
`more
`
`5:16, 7:22
`most
`12:17
`mouthful
`11:6
`mri
`
`3:16, 3:22,
`7:4, 7:7, 7:8,
`7:14, 11:14
`much
`
`5:1, 10:21
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`manufacturer
`13:1
`
`many
`5:6, 11:7,
`11:17, 13:3,
`13:8
`market
`12:11
`mavenclad
`
`1 2 4 4 4 5 6 7 8 9 9
`
`:8, 1:10, 2:4,
`25, 2:20, 3:17,
`25, 4:6, 4:10,
`2:16,
`7:18,
`:16,
`16,
`:18,
`2:16,
`:8,
`:
`
`716, 10:20,
`:1, 11:13,
`:14, 12:2,
`:6, 12:9,
`217, 13:1
`
`meaning
`2:17, 5:18
`means
`
`3:19, 9:22
`
`latent
`10:10
`later
`
`3:10, 6:22
`lauren
`
`1:22, 14:2,
`14:13
`least
`
`3:4, 6:21,
`8:15, 10:19,
`10:20, 11:11,
`11:20
`leaving
`2:13
`lesions
`
`3:16, 3:21,
`7:5, 7:6, 7:14
`lesser
`7:22
`let's
`4:3
`leukoencephalopa-
`thy
`11:6
`listed
`12:16
`little
`3:6
`live
`
`8:14, 11:8
`liver
`
`8:2, 8:3, 10:17
`look
`11:15
`looked
`6:17
`looking
`6:11
`looks
`2:16
`low
`
`9:10, 9:16
`lower
`7:15
`lymphocyte
`10:18, 12:4,
`12:6, 12:8
`lymphocytes
`4:11, 4:12,
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`6:9, 7:2, 8:3,
`8:8, 9:15,
`10:12, 10:15,
`11:13, 13:3
`paying
`12:19
`people
`2:11, 11:9,
`11:17, 12:18
`percent
`6:14, 7:2
`period
`7:7
`person
`2:18,
`3:19,
`6:18,
`12:5
`phase
`5:9, 6:1,
`place
`12:1
`placebo
`6:16
`
`6:17
`
`prescribe
`7:12
`
`prescribing
`4:5, 9:14
`prescriptions
`12:12
`
`pretty
`10:21
`
`prevent
`Os
`
`prevented
`9:3
`
`previous
`5:20
`price
`12:14
`prices
`12:16, 12:19
`primary
`3:2, 3:8, 6:10
`prior
`7:7, 10:16,
`10:19, 10:20
`process
`4:14
`
`processes
`4:8
`
`profile
`6:4
`
`program
`13:2
`
`progression
`6:18, 7:1, 7:15
`progressive
`2:8, 2:22, 3:1,
`3:2, 3:3, 3:8,
`3:9, 3:11, 3:13,
`3:18, 11:5
`progressively
`3:20
`protocol
`6:20
`provider
`13:15
`providers
`12:15
`putting
`8:10
`
`quite
`7:9
`
`raised
`12:11
`range
`12:8
`rare
`
`8:17
`rate
`
`6:12, 6:15,
`7:14, 7:15, 7:19
`rather
`
`4:18, 4:22,
`5:14
`reactivated
`10:11
`
`readily
`G 223
`reason
`
`11:19, 13:7
`recent
`
`3:20, 4:3
`recipient’s
`8:21
`recommend
`
`8:13, 10:13
`recommendation
`
`5:17, 5:18
`recommended
`12:9
`recorded
`1:7
`
`recording
`13:19, 14:3
`reduced
`7:1
`
`reducing
`13:11
`reduction
`
`6:11, 6:15,
`7:4, 7:14
`refer
`
`2:16, 3:14,
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`11:19
`only
`4:21, 10:1,
`11:14, 11:21,
`12:15, 13:17
`open
`13:15
`oral
`
`7:11, 11:11
`order
`5:22
`
`org
`1:10
`other
`2:22, 7:6,
`7:11, 7:22,
`12:13, 12:17
`otherwise
`14:9
`out
`8:2
`outcome
`14:9
`over
`
`5:5, 6:8, 13:17
`own
`
`8:21
`
`pages
`1:21
`
`part
`5:8
`particular
`4:9, 13:12
`particularly
`4:10, 4:12
`parties
`14:8
`
`past
`3:20, 4:3
`patient
`3:8, 10:7,
`10:22, 12:1,
`12:21, 13:1,
`13:13
`patients
`2:7, 2:19, 6:8,
`
`planet
`14:14
`
`planning
`11:20
`
`pml
`11:5, 11:7,
`11:10, 11:16
`point
`7:6, 11:18
`positive
`10:15
`possibility
`8:5
`potential
`7:13, 7:17,
`9:18
`potentially
`7:17, 9:9
`pregnancy
`9:19
`
`pregnant
`9:20, 10:5,
`11:2
`
`prepared
`14:3
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`referred
`6:22
`refers
`Bi 8
`reflect
`aD
`
`regard
`S22, 928
`regards
`9:8
`
`regimen
`4:17
`
`relatively
`4:3, 9:6, 12:22
`remember
`9:6
`
`remitting
`2:7, 2:10
`repair
`4:7
`reported
`11:10
`resolves
`2:12
`rest
`5:11
`risk
`
`9:9, 9:10,
`9:16, 10:10,
`11:4, 11:12,
`13:10
`risks
`
`7:21, 9:18,
`
`start
`11:17
`starts
`
`5:3, 8:20
`status
`
`8:12, 11:15
`stick
`11:7
`
`strong
`4:12
`strongly
`9:19
`substrate
`4:10
`superimposed
`3:10
`
`suppressed
`12:6
`sure
`
`10:18, 11:1
`switch
`11:21
`switching
`11:22
`syndrome
`2:17, 2:22
`synthesis
`4:7
`
`system
`11:13
`
`systems
`11:9
`
`T
`
`tablet
`
`4:18, 4:19
`tablets
`
`5:5, 5:6
`tag
`12:14
`take
`5:5
`taking
`7:2, 8:8, 9:19,
`9:20, 10:3
`talking
`2:4, 10:9
`term
`
`relapse
`2:12, 2:14,
`3:5, 3:16, 6:12,
`6:15, 7:14
`relapses
`2:11, 3:10,
`3:21, 6:12
`relapsing
`2:7, 2:10
`relate
`10:8
`related
`14:7
`relates
`8:22
`
`3:18
`
`13:11, 13:17
`robust
`7:4
`roughly
`5:10, 6:14
`routine
`10:17
`
`safe
`12:8
`safety
`6:4, 9:8, 12:10
`said
`14:4
`same
`
`5:15
`satisfactory
`6:4
`
`say
`4:3
`scan
`3:22
`scientific
`2:5
`sclerosis
`
`2:3, 2:8, 2:9
`screen
`
`10:12, 10:16
`screening
`10:13
`second
`
`5:8, 5:9, 5:10,
`5:13, 10:20
`second-line
`5:17
`
`secondary
`2:8, 3:2, 3:
`3:18
`see
`
`6:11
`serious
`7:17, 13:17
`serono
`12:22
`several
`2:10
`severe
`7:22
`
`shingles
`8:5, 8:8
`should
`
`8:15, 9:21,
`10:1, 10:3,
`10:5, 10:14,
`10:15, 11:14,
`13:14, 13:15
`shows
`6:18
`side
`
`7:18, 7:22
`signature-bi6ds
`14:11
`simply
`9:3
`situation
`
`8:19, 9:6
`six
`
`8:15, 10:4,
`10:5
`skills
`14:6
`slight
`7:20
`slightly
`7:19
`small
`12:22
`some
`
`2:13, 2:19,
`7:6, 7:20, 10:8,
`11:18, 11:19,
`12:4
`
`something
`2:16
`sometimes
`
`2:12, 3:10,
`11:19
`somewhat
`8:8
`
`specifically
`2:20, 4:4, 8:22
`specified
`6:20
`
`stage
`6:2
`stands
`1135
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`transcript
`14:3, 14:4
`transcription
`14:5
`transfused
`9:5
`transfusion
`9:2
`transfusions
`9:1
`transplanted
`8:20
`treat
`2:19
`treating-ms
`1:10
`treatment
`
`6:9
`
`terms
`7:11
`test
`11:14
`testing
`6:1, 6:2, 10:7,
`10:17, 10:22
`tests
`8:3
`theoretical
`11:12
`
`therapies
`13:8
`therapy
`5:18, 5:20,
`5:21, 12:10,
`13:6, 13:9
`thing
`8:17, 9:5,
`13:13
`things
`8:10
`think
`
`9:14, 10:21,
`13:13
`thinking
`4:2, 11:20
`thousand
`10:19
`three
`
`5:7, 6:6, 6:8,
`6:10, 6:21
`through
`6:1
`time
`
`3:4, 3:17, 3:22
`timing
`11:21
`tissue
`
`8:20, 8:21
`tolerability
`7:16, 13:18
`tolerated
`
`5:20, 7:19
`transcribed
`1:22
`transcriber
`14:1
`
`2:2, 2:21,
`4:17, 5:9, 5:11,
`8:16
`trial
`
`6:6, 6:7, 6:9,
`6:10
`true
`14:4
`tuberculosis
`10:12
`
`8:20
`
`types
`2:10, 3:1,
`9:12
`
`U
`
`:6,
`
`ultimately
`3:5
`understand
`9:15
`unfortunately
`12:13
`unique
`4:18
`until
`
`2:14, 10:4,
`10:5
`
`whenever
`7:11
`whether
`
`3:13, 6:11
`wholesale
`12:16
`woman
`
`9:18, 10:4,
`11:1
`women
`
`9:20, 10:4
`worse
`
`3:7, 3:20
`worsening
`6:19, 6:21
`www
`1:10
`
`Y
`
`year
`4:3, 5:12,
`5:13, 6:13
`$
`
`$99,000
`12:17
`
`1,000
`12:4
`
`1,300
`6:8
`10
`4:19
`14
`
`1:21, 14:15
`2
`
`2023
`14:15
`
`3-month
`6:22
`33
`7:1
`
`500
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`unusual
`
`8:19, 9:6
`use
`
`3:17, 4:9, 7:3,
`9:21, 10:1,
`10:16, 11:4,
`13:6
`
`usually
`4:1
`
`Vv
`
`vaccine
`
`8:14, 8:15
`variable
`13:11
`varicella
`
`8:6, 8:12,
`8:13, 8:14
`varieties
`4:15
`versus
`
`9:2, 13:10
`video
`1:7
`virus
`
`8:6, 8:15, 11:7
`WwW
`
`wait
`
`5:7, 12:7
`want
`
`10:18, 10:22,
`1i:1
`warning
`9:13, 9:14
`watch
`8:1
`we're
`2:3
`we've
`10:9
`weeks
`
`5:8, 8:16
`weighs
`5:1
`
`weight
`4:20, S27
`we’re
`b:4
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`
`
`Transcript of Video - What You Need to Know About Mavenclad
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`